C2VN

What C2VN does

C2VN (Centre de Recherche en CardioVasculaire et Nutrition) is a French public academic research center created on January 1, 2018 through the merger of three laboratories — NORT (Nutrition Obésité et Risque Thrombotique), VRCM (Vascular Research Center of Marseille), and MD2 (Dysoxie, système purinergique et inflammation). It operates as a mixed research unit (Unité mixte de recherche) under the triple tutelage of Aix-Marseille Université, INSERM, and INRAE, headquartered on the Timone Campus in Marseille, with a secondary administrative site at the Faculty of Medical and Paramedical Sciences / Faculty of Pharmacy (27 bd Jean Moulin, 13385 Marseille). The center comprises 9 research teams and 4 technological platforms — PIVMI (live cell imaging using Nanolive 3D holotomographic microscopy), AMUTICYT (cytometry and cell sorting), PMET (metrology), and CRIBIOM-BIOMET (biomolecular/biomeasurement characterization) — and as of May 2026 also hosts the newly created Institut Phocéen du Cœur et des Vaisseaux, a thematic institute of Aix-Marseille Université.

The center's research portfolio targets cardiovascular diseases and their prevention through nutrition, with specific focus on understanding nutritional, metabolic, and genetic factors driving cardiovascular pathogenesis, deciphering cellular and molecular mechanisms of thrombosis (with emphasis on endothelial cells, circulating cells, and extracellular vesicles), and translating fundamental findings into diagnostic, therapeutic, and nutritional targets for personalized vascular medicine. Notable scientific contributions include pioneering work on CD146 extracellular vesicles that selectively target atherosclerotic plaques to reduce vascular inflammation and atheroma burden (published in Atherosclerosis and European Heart Journal), thrombin generation assays combined with proteomic and GWAS analysis identifying complement proteins C5 and C9 as determinants of thrombin generation, deep-learning-based automated quantification of epicardial adipose tissue for cardiovascular risk stratification in type 2 diabetes, and multi-omic characterization of extracellular vesicles as circulating biomarkers.

C2VN has no commercial revenue model. It is funded through institutional allocations from its three supervisory public bodies, supplemented by competitive grants from programs such as the French Ministry of Health's RHU (5M EUR for INNOV-CKD in 2019), the Agence Nationale de la Recherche (JCJC for the MOST project in 2021), the Ministry of Research's rare disease program (BIOFIT in 2020), the A*Midex Méditerranée call (ADOSYN in 2019), and the ERA-net BIO-Belief consortium (2021). Its collaborators include Assistance Publique - Hôpitaux de Marseille for clinical research, CARNOT STAR for technology transfer, the ITN TICARDIO European training network, the Universities of Florence and Naples for Mediterranean research exchange, and IRBA for defense-related diving physiology work. The center's 'customers' are the academic and clinical research community — researchers, clinicians, and healthcare professionals engaged in cardiovascular and metabolic disease research — and its outputs are disseminated through scientific publications, conference presentations, and institutional partnerships rather than paid products or services.

Name

C2VN

Legal name

Centre de Recherche en Cardiovasculaire et Nutrition

Website

https://c2vn.univ-amu.fr

Company type

Private

Founded year

2018

Operating status

Operating

Headcount range

51–100 employees

Short description

C2VN is a French public academic research center (Unité mixte de recherche) under Aix-Marseille Université, INSERM, and INRAE, conducting cardiovascular and nutrition research across 9 teams and 4 technological platforms, serving the academic and clinical research community.

Ownership category

akta.pro rank

Product category

Cardiovascular Research

NAICS

Research and Development in the Physical, Engineering, and Life Sciences (54171)

SIC

Services-Medical Laboratories (8071), Laboratory Analytical Instruments (3826), In Vitro & In Vivo Diagnostic Substances (2835)

akta.pro industry

PRIMARYHLAJAOAM

Global Health Research, Clinical Trials & Product Development Partnerships (PDPs)

Healthcare & Life Sciences/Public Health, Government & Regulators/Global Health Initiatives & Partnerships

SECONDARYHLAFAMAL

Clinical Research & Trial Central Laboratories

Healthcare & Life Sciences/Healthcare Providers & Systems/Clinical Laboratories

SECONDARYHLAIACAG

Cardiology & Vascular Specialty Pharmaceuticals

Healthcare & Life Sciences/Pharmaceuticals/Specialty Pharmaceuticals

Keywords

• Cardiovascular research
• Nutrition science
• Extracellular vesicles
• Atherosclerosis research
• Translational medicine

Headquarters

HQ city

Marseille

HQ country

France

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Infrastructure, Operations

Distribution channels1 record

Marketing channels5 records

Core offering

C2VN is a French public cardiovascular and nutrition research center that conducts fundamental and translational research on cardiovascular disease mechanisms, thrombosis, atherosclerosis, and metabolic diseases. It operates 4 technological platforms (live cell imaging, cytometry, metrology, biomolecular analysis, mass spectrometry) and 9 research teams developing new diagnostic, therapeutic, and nutritional targets for personalized vascular medicine.

Product overview

C2VN (Centre de Recherche en CardioVasculaire et Nutrition) is a French research institution established January 1, 2018, operating under the triple supervision of Aix-Marseille Université, INSERM, and INRAE. The center comprises 9 research teams and 4 technological platforms. Its research portfolio includes extracellular vesicles and atherosclerosis studies, cardiovascular risk prediction, vascular medicine, micronutrition, thrombosis mechanisms, and cardiometabolic diseases. The center operates the Institut Phocéen du Cœur et des Vaisseaux thematic institute and provides access to specialized technological platforms including PIVMI (live cell imaging with Nanolive technology), AMUTICYT (cytometry), PMET (metrology), CRIBIOM-BIOMET (biomolecular analysis), and MS-Nutrition (mass spectrometry).

Differentiator

Problem solved

Functional benefit

Products and services

• PIVMI Platform (Plateforme d'Imagerie Vivoscope) Live cell imaging platform featuring Nanolive 3D Explorer microscope technology for real-time visualization of cells without staining or fluorescence markers, available to researchers at the C2VN center.
• AMUTICYT Platform
• PMET Platform
• CRIBIOM-BIOMET Platform
• MS-Nutrition Platform

Quantifiable outcome

• CD146 extracellular vesicles reduce inflammation and atheroma burden in atherosclerotic lesions
• +2 more outcomes

Segments1 record

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Ten partnerships are on record, tiered minor and core.

• IRBA (Institut de Recherche Biomédicale des Armées)minorStrategic or Co-development Partner · 1 January 2024Collaboration on diving research experiments with the French Navy, particularly with Dr Risso of Monaco Research Center and Cephismer.
• ERA-net BIO-Belief ConsortiumcoreStrategic or Co-development Partner · 1 September 2021C2VN coordinates the Nutrition work package of the BIO-Belief project (Dr Emmanuelle Reboul) focusing on developing drought-resistant, nutritionally improved common bean lines for sustainable diets.
• Marseille Luminy Immunology CenterminorStrategic or Co-development Partner · 1 January 2020Collaboration with Dr Dominique Payet-Bornet (CNRS) on the BIOFIT project for inherited thrombocytopenia biomarkers.
• INSERM U1251 Marseille Medical GeneticsminorStrategic or Co-development Partner · 1 January 2020Collaboration with Dr Michel Pucéat on BIOFIT project investigating inherited thrombocytopenia.
• University of Florence (Italy)minorStrategic or Co-development Partner · 1 October 2019Cross-border academic collaboration through the ADOSYN project, part of the A*Midex Méditerranée 2018 call, involving research exchange and joint activities.
• University of Naples - Federico II (Italy)minorStrategic or Co-development Partner · 1 October 2019Cross-border academic collaboration through the ADOSYN project strengthening Mediterranean research cooperation.
• CARNOT STARcoreStrategic or Co-development Partner · 20 September 2019C2VN is a partner in the CARNOT STAR network, which focuses on technology transfer and collaborative research in life sciences and health.
• ITN TICARDIOcoreStrategic or Co-development Partner · 20 September 2019Thrombo-inflammation in Cardiovascular Disease (TICARDIO) - European Training Network under the ITN program, bringing together academic institutions for research training in cardiovascular disease.
• Aix-Marseille Université (AMU)coreStrategic or Co-development Partner · 1 September 2019C2VN operates under triple tutelage of AMU as one of its key research laboratories, contributing to the university's interdisciplinary strategy including the new Institut Phocéen du Cœur et des Vaisseaux.
• Assistance Publique - Hôpitaux de Marseille (AP-HM)coreStrategic or Co-development Partner · 1 September 2019Clinical collaboration partner for the INNOV-CKD RHU project and other patient-oriented research studies in cardiovascular and renal diseases.

Scale indicators5 records

Recent moves8 records

Expansion highlights6 records

Direct peers

• PARCC (Paris Cardiovascular Research Center, INSERM U970): Major INSERM cardiovascular research unit in Paris covering atherosclerosis, thrombosis, and vascular biology — closely overlapping C2VN's core research domains and operating model as a Unité mixte de recherche.
• IHU ICAN (Institut de Cardiométabolisme et Nutrition): Paris-based institute focused on cardiometabolism and nutrition, sharing C2VN's exact dual focus on cardiovascular disease and nutritional prevention. Operates translational research programs with similar academic-clinical partnerships.

Regional players

• Max Delbrück Center for Molecular Medicine (MDC): Berlin-based biomedical research center with strong cardiovascular and metabolic disease programs; comparable in being a multi-team public research institution with platform infrastructure.
• CNIC (Centro Nacional de Investigaciones Cardiovasculares Carlos III): Spain's national cardiovascular research center with comparable multi-team structure and a translational cardiovascular focus; operates as a public research foundation similar to C2VN but with greater scale and international visibility.
• Montreal Heart Institute: Canadian cardiovascular research hospital integrating basic science, clinical research, and patient care — directly comparable to C2VN's translational model and academic-clinical partnership structure.

Broad incumbents

• INSERM: C2VN's parent supervising institution and France's national health research agency; broader portfolio spanning all biomedical fields, providing scientific governance and funding infrastructure to C2VN.
• Institut Pasteur: Premier French life-sciences research foundation; comparable operating model (public research foundation, multi-team structure, biomedical platforms) but with broader infectious disease and immunology focus.
• INRAE: Co-supervising parent institution for C2VN; France's national research institute for agriculture, food, and environment — covering C2VN's nutrition axis as part of a much larger food-and-health portfolio.

Others

• British Heart Foundation: Major non-profit funder and coordinator of cardiovascular research in the UK; functions as an enabler/ecosystem participant similar to how French ministries and INSERM support C2VN, though operating as a charity rather than research performer.
• Karolinska Institutet: Major European medical university with extensive cardiovascular and metabolic disease research programs; thematically related through cardiovascular-nutrition research rather than directly comparable as an operating entity.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights7 records

Customer concentration

• Xx.com/reseau_c2vn
• LinkedInlinkedin.com/company/c2vnofficiel

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about C2VN